UCB gets access to rights for an antibody programme from WILEX for non-oncology indications

11-Jul-2013 - Germany

WILEX AG and UCB announced that UCB has acquired an antibody programme from WILEX’ preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the programme in any indication outside the field of oncology, while WILEX keeps the rights to develop for oncology indications.

WILEX will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments as well as royalties.

UCB and WILEX will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these antibodies in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to WILEX the relevant data to assist WILEX in oncology.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous